Details for Patent: 11,969,503
✉ Email this page to a colleague
Which drugs does patent 11,969,503 protect, and when does it expire?
Patent 11,969,503 protects XATMEP and is included in one NDA.
This patent has three patent family members in three countries.
Drugs Protected by US Patent 11,969,503
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | XATMEP | methotrexate sodium | SOLUTION;ORAL | 208400-001 | Apr 25, 2017 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,969,503
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2614814 | ⤷ Subscribe | |||
| Spain | 2726524 | ⤷ Subscribe | |||
| United Kingdom | 201200192 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
